What question did this study set out to answer?

The aim is to extend the Identity Axis Framework to prion diseases to identify unique characteristics and treatment strategies.

March 12, 2026Open Access

Prion Diseases as Attractor Medicine: Conformational False Attractors, Cross-Species Resistance, and Drug Target Derivation from the Identity Axis Framework

Key Points

The aim is to extend the Identity Axis Framework to prion diseases to identify unique characteristics and treatment strategies.
Introduced the concept of protein conformational false attractors.
Validated R_PRION coordinate against cross-species resistance data.
Examined genetic evolution in the Fore people and its implications.
Derived new drug logic for prion intervention.
Prion diseases show unique characteristics distinct from other protein misfolding disorders.
Amino acid changes can confer complete resistance to prion diseases.
Proposed drug strategies include substrate removal and conformation stabilization.
Introduced permanent synthetic interventions as equivalents to natural evolution.

Abstract

This paper extends the Identity Axis Framework (R = A/H) — previously applied to cancer, neurodegeneration, and psychiatric disease — to prion diseases, establishing a new table class: the protein conformational false attractor (Class 2 / Level 4). We derive why prion diseases are geometrically distinct from all other entries in the Attractor Medicine table: the unit of identity failure is not a cell but a single protein molecule, and the false attractor (PrPSc, beta-sheet conformation) is thermodynamically self-maintaining without an enzymatic Hub. The RPRION coordinate (energy barrier to false conformation / PrPSc templating efficiency) is introduced and validated against the cross-species resistance data: dogs (D163), rabbits (S174), horses (S167), and the Fore people of Papua New Guinea (G127V, Mead et al. , NEJM 2015). The Fore G127V evolution — complete prion resistance from a single amino acid change in four generations — is identified as the clearest documented case of natural selection raising RPRION by reinforcing the Identity Anchor of a protein. The standard Tier 2 Hub inhibitor drug logic fails for prion disease (the Hub is not a separate enzyme but the misfolded conformation itself), and the correct drug logic is derived to be substrate removal (ION717 PRNP-ASO, Phase 1/2, 2024) combined with conformation stabilisation (anle138b). A Tier 3 intervention — base editing G127V in PRNP — is derived as a permanent synthetic equivalent of the Fore evolution. The document introduces the four-level taxonomy of identity failure (gene regulatory, circuit connectivity, temporal/phase, protein conformational), unifies the Level 4 drug platform across all propagating protein diseases (prion, Alzheimer's tau, Parkinson's alpha-syn, Huntington's mHTT, ALS TDP-43), and derives the coupling between lifespan extension and sporadic CJD risk as a direct implication of the anti-aging framework. Nine claims are verified against published evidence; three novel predictions are locked with this timestamp.

Prion Diseases as Attractor Medicine: Conformational False Attractors, Cross-Species Resistance, and Drug Target Derivation from the Identity Axis Framework

Key Points

Abstract

Cite This Study

Also Consider

Also Consider